Adalimumab Market To Reach $21.5 Billion by 2035

Adalimumab market is projected to grow from $10.8 billion in 2025 to $21.5 billion by 2035, registering a CAGR of 7.1% during the forecast period from 2026 to 2035. Rising prevalence of autoimmune disorders, increasing biologic therapy adoption, and expanding biosimilar penetration are major growth drivers supporting global market expansion. According to the World Health Organization, approximately 18 million people worldwide were living with rheumatoid arthritis in 2019, with autoimmune disorders continuing to increase globally due to aging populations and chronic inflammatory disease burden. This growing patient population is significantly driving demand for TNF-alpha inhibitors such as adalimumab across hospitals, specialty clinics, and home care settings. Additionally, the U.S. FDA continues to accelerate biosimilar approvals to improve biologic affordability and treatment access. Among product categories, Biosimilar Adalimumab is anticipated to emerge as the fastest-growing segment due to favorable regulatory policies, aggressive pricing competition, and expanding interchangeability approvals. Biosimilar adoption is increasing rapidly across North America and Europe as healthcare systems seek cost-effective biologic treatment alternatives for chronic inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis.

Browse the full report description of “Adalimumab Market Size, Share & Trends Analysis Report, By Product Type (Original/Breference Adalimumab, Biosimilar Adalimumab), By Treatment Stage (First-line Biologic Therapy, Second-line Biologic Therapy, Maintenance Therapy), By End User (Hospitals, Specialty Clinics, Ambulatory Infusion Centers, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/adalimumab-market

Further supporting this growth trajectory, the market is also benefiting from strong pipeline development and increasing strategic collaborations between originator biologic manufacturers and biosimilar developers aimed at improving manufacturing efficiency and global distribution. Continuous advancements in monoclonal antibody engineering, coupled with large-scale investment in biomanufacturing capabilities, are enhancing production scalability and reducing overall therapy costs. In addition, expanding healthcare coverage in emerging economies and growing physician confidence in biosimilar efficacy and safety profiles are accelerating treatment uptake. The increasing shift toward value-based healthcare models and hospital cost-containment strategies is further reinforcing the adoption of adalimumab therapies across both branded and biosimilar segments globally.

Ket leaders transforming the adalimumab market

• In February 2024, Alvotech and Teva Pharmaceutical Industries Ltd. received U.S. FDA approval for SIMLANDI (adalimumab-ryvk), the first interchangeable high-concentration, citrate-free biosimilar to Humira, strengthening competition in the adalimumab biosimilars market and expanding access to lower-cost biologic therapies.

• In January 2023, Amgen launched AMJEVITA (adalimumab-atto), the first biosimilar to Humira available in the U.S., expanding access to lower-cost adalimumab therapies and intensifying competition in the global adalimumab biosimilars market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• By Product Type
• By Treatment Stage
• By End-User Industry
• Competitive Landscape – AbbVie, Amgen, Samsung Bioepis, Sandoz (Novartis), Boehringer Ingelheim, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Adalimumab Market Report Segment

By Product Type

• Original/Breference Adalimumab
• Biosimilar Adalimumab

By Treatment Stage

• First-line biologic therapy
• Second-line biologic therapy
• Maintenance therapy

By End User

• Hospitals
• Specialty clinics
• Ambulatory infusion centers
• Homecare settings

Global Adalimumab Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/adalimumab-market